NCT00638703View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Primary Hyperoxaluria
Interventions
BIOLOGICAL

Oxalobacter formigenes

NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks

DRUG

Placebo

placebo

Trial Locations (1)

55905

Mayo Clinic (Department of Pediatric Nephrology), Rochester

Sponsors

Lead Sponsor

OxThera
All Listed Sponsors
lead

OxThera

INDUSTRY

NCT00638703 - Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients | Biotech Hunter | Biotech Hunter